Abstract 3051
Background
A better identification of patients who are more likely to benefit from immune checkpoint inhibitors is warranted in advanced non-small cell lung cancer (NSCLC). In resent preclinical study, obesity was associated with increased efficacy of PD-1/PD-L1 blockage. Herein, we conducted a retrospective study to investigate the prognostic accuracy of body mass index (BMI) and computed tomography-defined fat area in patients with advanced NSCLC treated with nivolumab.
Methods
We retrospectively analyzed patients with advanced NSCLC who received nivolumab at our institute between January 2016 and January 2019. Clinical data including BMI, visceral fat area (VFA) and subcutaneous fat area (SFA), and progression free survival (PFS) were collected. Treatment outcome of nivolumab was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
Results
In total, 126 patients were included in this study. High VFA (≥100cm2) were significantly associated with longer PFS, whereas high SFA (≥100cm2) and high BMI (≥25) were not. The objective response rates were higher in patients with high VFA than in those with low VFA (39% versus 19%; [P = 0.027], respectively). In multivariate analysis, high VSA (hazard ratio: 0.61, 95% confidence interval: 0.40–0.93; [P = 0.022]) and better PS (hazard ratio:0.35, 95% confidence interval: 0.19–0.68; [P = 0.003]) were identified as an independent predictor of longer PFS in patients treated with nivolumab.
Conclusions
In patients with advanced NSCLC who received nivolumab, high VFA were independent predictors of nivolumab efficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kobe City Medical Center General Hospital.
Funding
Has not received any funding.
Disclosure
Y. Sato: Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd. D. Fujimoto: Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd. K. Hosoya: Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
5995 - Invasive fungal diseases caused by rare pathogens in patients after hematopoietic stem cell transplantation (HSCT) & chemotherapy
Presenter: Yuliya Rogacheva
Session: Poster Display session 1
Resources:
Abstract
2961 - Safety and pharmacokinetics of novel CXCR4 antagonist YF-H-2015005 in the mobilization of hematopoietic stem cells in patients with non-Hodgkin's lymphoma
Presenter: Weiping Liu
Session: Poster Display session 1
Resources:
Abstract
5771 - Chemotherapy associated Hyponatremia in Hematological Malignancies: A retrospective study of 189 patients treated in a single medical center
Presenter: Vadim Lesan
Session: Poster Display session 1
Resources:
Abstract
1165 - Risk factors for Bacteremia-Associated Mortality of Aeromona sobria in Hematologic Malignancies
Presenter: Gabriel De la Cruz-Kú
Session: Poster Display session 1
Resources:
Abstract
5287 - Use of droplet digital polymerase chain reaction for detecting minimal residual disease: a prospective, multi-institutional study
Presenter: Hyunkyung Park
Session: Poster Display session 1
Resources:
Abstract
1886 - RUBIH2 — Use of NGS in haematological malignancies: from real world data to national recommendations, an innovative program to evaluate the impact of healthcare technology on patient care
Presenter: Severine Coquerelle
Session: Poster Display session 1
Resources:
Abstract
1940 - Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1946 - Is bone marrow examination indispensible in chronic myeloid Leukemia at diagnosis ?
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1904 - Incidence of Imatinib Resistance in Chronic Myeloid Leukemia (CML) Patients: Experience from Resource Poor Centre of Eastern India
Presenter: Debmalya Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
3245 - BCR-ABL transcript variant’s significance in chronic myeloid leukemia in chronic phase: Institutional experience from a developing country
Presenter: Siva Prasad
Session: Poster Display session 1
Resources:
Abstract